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A B S T R A C T
Purpose: Previous studies show anti-epileptic drug compliance and seizure control in people with
epilepsy (PWE) to be lower among low-income groups and African-Americans. We examined how socio-
demographic factors inﬂuence seizure control in an inner-city population.
Methods: The clinic records of 193 PWE were analyzed. Good seizure control was deﬁned as no seizures
in the previous year. Bivariate and multivariate analyses were performed to examine the effects of race,
age, gender, median household income, medication cost, and insurance status on good seizure control.
Results: There were 69 Caucasians and 124 African-Americans (age 47.8  16.5 years) in the study.
African Americans had a signiﬁcantly lower income than Caucasians (p < 0.001); but did not have inferior
seizure control (p = 0.18). Seizure control was also not affected by gender (p = 0.82), AED costs (p = 0.06),
insurance type (p = 0.20), or race-independent household income (p = 0.75).
Conclusion: Contrary to prior literature, we ﬁnd that in our population of PWE there were no signiﬁcant
effects of race or family income on seizure outcomes. Our ﬁndings add to the existing literature on socio-
demographic disparities in PWE and merit further exploration by other groups
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Elimination of disparities in health and health care are
extremely high public health priorities in the US,1 but Neurology
lags behind other medical specialties in such research.2 As with
other chronic diseases, epilepsy is impacted by various social,
economic and cultural factors. However, research on the role of
socio-demographic factors such as race/ethnicity, gender, age, and
insurance status on medical treatment and outcomes in people
with epilepsy (PWE) is lacking, and at times conﬂicting.3,4
Epidemiologic studies have shown higher rates of epilepsy in
African-Americans and Hispanics compared to non-Hispanic
Caucasians.5,6 African-Americans have been noted to be less likely
to receive anti-epileptic drugs (AEDs),7 or be compliant with AEDs
prescribed,8–10 and more likely to have visits to generalists 11 and
Emergency Rooms9,11 or to be hospitalized.11,12 African-Americans
are also less likely to undergo epilepsy surgery.13,14 Status
epilepticus15 and age-adjusted mortality due to epilepsy were
also found to be higher in black patients.16 One study looking intoAbbreviations: AED, anti-epileptic drug(s); PWE, people with epilepsy.
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http://dx.doi.org/10.1016/j.seizure.2014.01.002the underlying causes of racial disparity in epilepsy found four
major obstacles to optimal care: limited ﬁnancial resources, lack of
knowledge about epilepsy, poor patient-provider communication,
and lack of social support.17 The ﬁndings of disparity in epilepsy
are not surprising in the context of similar socio-demographic
disparity reported in other chronic conditions such as asthma,18–20
end-stage renal disease,21 cancer,22,23 invasive pneumonia,24 and
bariatric surgery 25 among others. On the other hand, there also
exists literature which has failed to ﬁnd racial disparity in epilepsy
epidemiology, care or outcomes. In contrast to the above-
mentioned reports, some epidemiologic studies did not ﬁnd a
racial difference in the incidence of epilepsy.26,27 A recent study
found increased generalist and emergency room visits among
African-Americans compared to Caucasians, and among lower-
income compared to higher income PWE, but these effects were
seen to be dependent on the center in this multi-center study:
controlling for the center in the statistical model negated the
signiﬁcance of these ﬁndings.11
Based on the previous literature on disparity in epilepsy, we
planned to explore the association of socio-demographic variables
and epilepsy treatment outcomes in our patient population. In this
study we evaluated a racially heterogeneous outpatient epilepsy
population to examine different socio-demographic and health-
care variables including age, gender, race, family income, cost of
medications, and insurance type and their association with
treatment outcomes as reﬂected by seizure control.Epilepsy Association.
Table 1
Monthly calculated expense for anti-epileptic drug generic substitutes used in our
patients.
Medication Median dose Cost/month
Carbamazepine 200 QID $19
Gabapentin 800 TID $73
Lacosamide 150 BID $437
Lamotrigine 100 BID $30
Levetiracetam 750 BID $35
Oxcarbazepine 300 BID $129
Phenobarbital 60 TID $12
Phenytoin 100 TID $32
Pregabalin 200 BID $176
Primidone 250 TID $70
Topiramate 200 BID $50
Valproic acid 750 TID $54
Zonisamide 300 daily $180
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The study was approved by the Institutional Review Board at
the Drexel University College of Medicine (DUCOM), and was
performed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki. Written informed consent was
not deemed necessary for this retrospective chart review.
2.1. Recruitment and data collection
The clinic charts of all patients aged 18 and older attending the
epilepsy clinic at Drexel University College of Medicine, Philadel-
phia between 2008 and 2010 were reviewed. A cross-sectional
analysis of prevalent cases of epilepsy on anti-epileptic medica-
tions was performed. Patients without a clear history of epilepsy,
possible non-epileptic seizures or syncope, migraines and patients
not on antiepileptic drugs were excluded. Race information was
abstracted from the clinical record demographics as self-identiﬁed
by the patients. Data on race is routinely collected as part of the
outpatient demographics at Drexel University. Patients belonging
to races other than non-Hispanic Caucasians and African-Amer-
icans were also excluded as the numbers were too small for
meaningful sub-group analyses. Data collected included age,
gender, race, insurance type, current AED, home zip code, age at
seizure onset, duration of epilepsy, and seizure control as
represented by seizure frequency. The data collected was from
the demographic information of the medical record and from the
progress note of the treating epileptologist. Ultimately, 193
patients were included for statistical analyses. The primary
objective of this study was to determine whether socioeconomic
factors speciﬁcally race, gender, household income, cost of
medications and insurance status are associated with epilepsy
control.
2.2. Data coding and calculations
Seizure control as documented in the clinical notes was coded
as ‘good control’ if there were no seizures in the one year prior to
clinic visit, and as ‘poor control’ otherwise in line with previous
research.28 As has been done in previously published health
outcomes research, the median household income of patients were
calculated from the US census data (2000) of race-speciﬁc median
household income compared to the patient’s zip code.18,19
Following the methodology of previous research, we calculated
the cost of medications based on the generic price for an estimated
median dose of AED (available from drugstore.com, Table 1).29
2.3. Statistical analysis
To assess the impact of socio-demographic variables on
treatment outcomes (good vs. poor seizures control) and race
(Caucasian vs. African-American), chi-squared tests (for gender,
insurance status) and t-tests (for age, household income, cost of
medications) were used. To examine the effect of race-indepen-
dent income on seizure control, the incomes of all patients were
divided into quartiles and compared to the medication costs using
ANOVA. Logistic regression of the variables was performed for
multi-variable analysis. Statistical analyses were performed using
PASW Statistics, Release Version 19.0.0 (SPSS, Inc., 2010, Chicago,
IL, www.spss.com).
3. Results
Of the 193 records analyzed, there were 120 females and 73
males with a mean age of 47.8  16.5 years.3.1. Seizure control and socio-demographic variables
The different socio-demographic and health related variables
were compared to seizure control (Table 2) and are detailed below.
3.2. Race
There were 124 African Americans and 69 Caucasians included
in the analyses. Good seizure control was found in 68 patients
(35.2%) and poor seizure control in 125 patients (64.8%). Race did
not impact seizure control (x2 test, p = 0.18; odds ratio 1.54 [C.I:
0.82-2.92]).
3.3. Household income
The household income was not signiﬁcantly different between
patients with good control and those with poor control. Race-
speciﬁc differences in income and seizure control are detailed
below (‘‘Race and socio-demographic/outcome variables’’). To
examine the effect of race-independent household income on
seizure control, the family income of all patients were divided into
quartiles of income and seizure control compared between the
groups (data not shown). There was no signiﬁcant difference in
seizure control between different race-independent income
groups (x2 test, p = 0.75).
The median household income (SD) for patients with Medicare
($35,928  $13,614), Medicaid ($32,929  $11,741) or Private insur-
ance ($32,520  $14,057) were not signiﬁcantly different (ANOVA
p = 0.49).
3.4. AEDs
Poor seizure control was associated with the use of more AEDs
(Figure 1A. x2 test, p = 0.03) and a non-signiﬁcant trend toward
higher cost of medications (p = 0.06). However, the higher cost was
likely contributed by outliers as a box and whisker plot showed
similar distribution of medication costs between the two groups
with a smaller number of patients in the poor control group having
a higher medication cost (Figure 1B). The total cost of AEDs did not
change as a function of insurance type (p = 0.60).
3.5. Race and socio-demographic/outcome variables
The income for African Americans was signiﬁcantly lower than
Caucasians in line with the national census data. The median
household income for Caucasians in our group ($44,136) was
similar to the national average household income for Caucasians
($44,687) in the 2000 census. The median household income for
African-Americans ($26,935) was lower than the national average
Table 2
Association between socio-demographic variables and seizure control in PWE.
Poor control (n = 125) Good control (n = 68) Signiﬁcance (p value)
Race (AA/Caucasian) 76/49 48/20 0.18
Age (years) 46.3( 16.4) 50.6( 16.3) 0.08
Gender (female/male) 77/48 43/25 0.82
Household income $33,941( $14,406) $31,510( $11,955) 0.24
Cost of medications $82.4( 63.1) $63.2( 48.6) 0.06*
Insurance status (Medicare, Medicaid, Private) 14/23/88 14/10/44 0.20
* trend ** signiﬁcance
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Caucasians and African Americans in the cost of medications
($70.8  62.5 and $78.3  72.0 respectively, p = 0.47) or insurance
type (PWE on Medicare/Medicaid/Private insurance- 12/10/47 and
16/23/85 respectively, p = 0.59).
3.6. Multivariate analysis
Multivariate regression of the various variables (gender,
insurance status, household income, age, medication cost and
race) against seizure control (poor v. good control) revealed a trend
for higher medication costs to be associated with poor seizure
control (p = 0.06). The other variables did not reveal signiﬁcant
difference based on seizure control.
4. Discussion
We evaluated a unique inner-city population consisting of both
Caucasian and African-American PWE to determine if socio-
economic factors such as race, gender, household income, cost of
medications or insurance status are associated with epilepsy
control. Our analysis did not reveal an effect of race, gender,
household income or insurance type on seizure control.
Control of epilepsy was worse in our study (64.8%) compared to
a previous study (40.8%) which used similar criteria to deﬁne good
seizure control28 and from other previous reports (30-40%) of
pharmacoresistant epilepsy.30,31 This was thought to be due to the
more severe cases of epilepsy that get referred to our specialist
clinic from the General Neurology practice in our hospital and from
outside referrals.
4.1. Race and family income
Previous research in epilepsy has found a signiﬁcant difference
in control of disease based on race 9,11,12 or income. 11 In our group,
we found that Caucasians and African-American PWE have similarFig. 1. (a) Number of PWE on one, two, three and four AEDs having poor (green) and goo
seizure control.seizure control, although family income was lower for African-
Americans. The incidence of epilepsy has been reported to be
higher in African-Americans.6 African-American patients are more
likely to be under-treated, have subtherapeutic AED levels and
attend the Emergency Room more frequently.7,9,11,12 Interestingly,
the most recent of these studies was a multi-center study that
found more generalist visits, hospital admissions and Emergency
Room visits among Black and Hispanic patients, but determined
these effects to be dependent on the site of treatment.11 One of the
sites in this study catered to a largely middle-class population,
while three other sites served a lower socio-demographic
population. Controlling for the site in the statistical model
decreased the magnitudes and signiﬁcance of the observed
sociodemographic disparities substantially. It would appear that
there is more to the apparent socio-demographic disparity in
epilepsy care than race and income per se: the authors suggest that
there could be unmeasured clinical/personal patient character-
istics such as seizure severity or patient attitudes and beliefs
inﬂuencing treatment outcomes.11 Such a site-to-site disparity
could explain why we did not ﬁnd a difference in seizure control
based on race or family income in contrast to some of the other
previous reports. A ‘neighborhood-level effect’ on health-care
disparities has also been reported for other disease conditions such
as HIV treatment 32 and cardiovascular care.33 Moreover, in our
study, analysis of seizure control against household income
independent of race did not show a signiﬁcant difference. Previous
studies have shown worse control of disease in poor patients with
epilepsy.11 Our ﬁndings are thus relevant in demonstrating that
socio-demographic disparity is not universal as other recent
research has suggested. It would be interesting to see if treatment
at a comprehensive epilepsy center may have contributed to an
improved outcome in African-Americans and low income groups
leading to a negation of the previously reported race effect on
epilepsy control. The geographic locations that comprise the
catchment area of our outpatient clinic would lead to some
homogeneity of socio-economic factors between groups.d (blue) seizure control. (b) Estimated total AED costs in PWE having poor and good
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average household income, there was a signiﬁcant difference in
income based on race (African-Americans vs. Caucasians), which
also did not result in a difference in seizure control.
4.2. Anti-epileptic drugs
Unsurprisingly, we found an association between poor seizure
control and greater number of AEDs used: patients with poor
seizure control would be expected to be on a larger number of
medications. Further analysis did not reveal an association
between medication cost and seizure control. It should be noted
that medication costs do not accurately reﬂect treatment intensity
due to potential non-compliance and wide variability in AED costs.
PWE who are poor are likely to be non-compliant with medica-
tions, likely due to inability to afford medications.34
4.3. Insurance
There is a perception among Neurologists of variability in the
ease of obtaining the prescribed AED or brand name formulations
depending on insurance type, potentially affecting seizure control.
Most American citizens receive health insurance coverage through
the private sector. Public sector programs exist to provide health
insurance to citizens that meet certain eligibility requirements and
also for those who cannot obtain private health insurance.
Medicare is a federally-funded insurance program largely for
citizens of age 65 years and older. Medicaid, by contrast, is funded
both by federal and state governments, and provides health
insurance to citizens that fall below a certain income and asset
baseline. Few studies have assessed how the type of insurance
affects epilepsy treatment and outcomes. We did not ﬁnd an
association between the type of insurance (Medicare, Medicaid or
Private) and cost of AED prescribed or seizure control. Uninsured
patients have been reported to be less compliant with anti-
epileptic drug therapy compared to patients with insurance.8 In a
study assessing patients with seizures presenting to the Emergen-
cy Room, only 39% were found to have any insurance other than
state coverage.9 Compared to private insurance, Medicare coverage
was found to be associated with an increased likelihood in
attending the Emergency Room or getting admitted to the
hospital.11 To our knowledge, these are the only studies which
investigated how the type of insurance affects epilepsy treatment.
It has not been documented whether insurance company policies
affect the AED prescribed or seizure control. We could not
speciﬁcally examine whether patients on particular types of
insurance were more likely to get brand versus generic medica-
tions. Some studies have reported better seizure control with
brand, as opposed to generic, medications.35,36 However, if
particular insurance types were more likely to approve brand
name medications, the effect was not measurably translated into
eventual outcomes as we did not ﬁnd an association between
insurance type and seizure control. We also did not ﬁnd an
association between family income and insurance type.
4.4. Limitations
The study had limitations intrinsic to retrospective studies. We
used strict inclusion criteria to include only patients in whom all
the relevant information was available to minimize these
limitations. This study has been unable to determine the
relationship between certain races and treatment outcomes,
which were not included in this study. These included Hispanics
and Asians, for whom we lacked a large enough sample size to
provide meaningful statistical analysis. Although Hispanics formed
about 13% of the population in the city of Philadelphia as per the2010 US census, in the center city area, where our hospital is
located, they constitute only about 3-8% of the population. Another
potential reason for underrepresentation of certain racial sub-
groups may be their limited access to organized healthcare. It is
possible that particularly adverse socioeconomic status and
consequent limitations in access to quality healthcare affects
outcomes, including epilepsy control, in these subgroups. It is
unclear how these patient groups can be better represented in the
literature, so that the problems they face are better documented
and solutions sought. Multicenter studies could suffer from similar
shortcomings. Population surveys may provide some information,
but it would be impractical to collect detailed information for
every clinical condition. Many previous surveys including the
NHANES (National Health and Nutrition Examination Survey) in
the USA have, perhaps justiﬁably, paid greatest attention to
cardiovascular disease. Perhaps the selection of epilepsy as an
additional ‘‘focus area’’ in future large surveys may clarify some of
these issues. Local socio-cultural factors including compliance and
attitudes towards treatment may affect treatment outcome32,33
which could limit the generalizability of our results. However it is
still important to document that there are specialized sub-
populations that have a different socio-demographic effect on
seizure control than larger population studies. Determining the
factors responsible for such a disparity such as treatment at
specialized epilepsy centers could guide future policy. Our patient
population of more refractory epilepsy also limits generalization of
our results. Although the cost of medications prescribed and
seizure control were similar in all income groups, it is possible that
compliance may have differed based on social or economic
factors.8 A potential advantage of the use of brand name
medications over generics35,36 could not be evaluated in our
analysis. In our study, the numbers of PWE having different types
of private insurance were too small to assess treatment or outcome
differences between them.
5. Conclusions
We ﬁnd that in our population of PWE, there were no signiﬁcant
effects of race or family income on seizure outcome. Our study
adds to the existing literature which has mostly found a negative
impact of African-American race or poor economic status on
various indices of epilepsy epidemiology, treatment and outcome.
Our ﬁndings are in line with recent research which has uncovered
site-speciﬁc variability in these indices.11 Further exploration of
these measures by other groups is essential in providing a broader
vision of the status of socio-demographic disparities in epilepsy
care. Uncovering speciﬁc causes of site-to-site variability of the
socio-economic impact on seizure control may help guide health
care policy.
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